Abnormal 0 8 0 8 B-chronic_disease
cardiac 9 16 9 16 I-chronic_disease
function 17 25 17 25 I-chronic_disease
defined 26 33 26 33 O
by 34 36 34 36 O
a 37 38 37 38 O
left 39 43 39 43 B-clinical_variable
ventricular 44 55 44 55 I-clinical_variable
ejection 56 64 56 64 I-clinical_variable
fraction 65 73 65 73 I-clinical_variable
( 74 75 74 75 I-clinical_variable
LVEF 75 79 75 79 I-clinical_variable
) 79 80 79 80 I-clinical_variable
of 81 83 81 83 O
< 84 85 84 85 O
50 85 87 85 87 B-upper_bound
% 87 88 87 88 I-upper_bound

Aged 0 4 89 93 B-age
less 5 9 94 98 O
than 10 14 99 103 O
18 15 17 104 106 B-upper_bound
years 18 23 107 112 I-upper_bound

Any 0 3 113 116 O
of 4 6 117 119 O
the 7 10 120 123 O
following 11 20 124 133 O
within 21 27 134 140 O
6 28 29 141 142 B-upper_bound
months 30 36 143 149 I-upper_bound
prior 37 42 150 155 I-upper_bound
to 43 45 156 158 O
study 46 51 159 164 O
enrolment 52 61 165 174 O
: 61 62 174 175 O
infectious 63 73 176 186 O
or 74 76 187 189 O
inflammatory 77 89 190 202 B-chronic_disease
bowel 90 95 203 208 I-chronic_disease
disease 96 103 209 216 I-chronic_disease
, 103 104 216 217 O
diverticulitis 105 119 218 232 B-chronic_disease
, 119 120 232 233 O
gastrointestinal 121 137 234 250 B-chronic_disease
perforation 138 149 251 262 I-chronic_disease
, 149 150 262 263 O
intestinal 151 161 264 274 B-chronic_disease
obstruction 162 173 275 286 I-chronic_disease
, 173 174 286 287 O
and 175 178 288 291 O
gastrointestinal 179 195 292 308 B-chronic_disease
hemorrhage 196 206 309 319 I-chronic_disease

At 0 2 320 322 O
least 3 8 323 328 O
one 9 12 329 332 B-lower_bound
lesion 13 19 333 339 I-lower_bound
amenable 20 28 340 348 O
to 29 31 349 351 O
biopsy 32 38 352 358 B-treatment

At 0 2 359 361 O
least 3 8 362 367 O
one 9 12 368 371 B-lower_bound
measurable 13 23 372 382 O
lesion 24 30 383 389 O
by 31 33 390 392 O
RECIST 34 40 393 399 O
v1.1 41 45 400 404 O
in 46 48 405 407 O
the 49 52 408 411 O
Expansion 53 62 412 421 O
Phase 63 68 422 427 O
only 69 73 428 432 O

Availability 0 12 433 445 O
of 13 15 446 448 O
archived 16 24 449 457 O
tumor 25 30 458 463 B-cancer
tissue 31 37 464 470 O
for 38 41 471 474 O
carcinoembryonic 42 58 475 491 B-treatment
antigen 59 66 492 499 I-treatment
- 66 67 499 500 I-treatment
related 67 74 500 507 I-treatment
cell 75 79 508 512 I-treatment
adhesion 80 88 513 521 I-treatment
molecule 89 97 522 530 I-treatment
5 98 99 531 532 I-treatment
( 100 101 533 534 I-treatment
CEACAM5 101 108 534 541 I-treatment
or 109 111 542 544 I-treatment
CEA 112 115 545 548 I-treatment
) 115 116 548 549 I-treatment
testing 117 124 550 557 O

Cardiac 0 7 558 565 B-chronic_disease
conduction 8 18 566 576 I-chronic_disease
defects 19 26 577 584 I-chronic_disease

Concurrent 0 10 585 595 O
treatment 11 20 596 605 B-treatment
with 21 25 606 610 O
any 26 29 611 614 O
other 30 35 615 620 O
anticancer 36 46 621 631 B-treatment
therapy 47 54 632 639 I-treatment

Contraindications 0 17 640 657 O
to 18 20 658 660 O
the 21 24 661 664 O
use 25 28 665 668 O
of 29 31 669 671 O
ophthalmic 32 42 672 682 B-treatment
vasoconstrictor 43 58 683 698 I-treatment
and/or 59 65 699 705 O
corticosteroid 66 80 706 720 B-treatment
as 81 83 721 723 O
per 84 87 724 727 O
package 88 95 728 735 O
insert 96 102 736 742 O
of 103 105 743 745 O
each 106 110 746 750 O
drug 111 115 751 755 O
, 115 116 755 756 O
including 117 126 757 766 O
the 127 130 767 770 O
following 131 140 771 780 O
: 140 141 780 781 O
increase 142 150 782 790 O
intraocular 151 162 791 802 O
pressure 163 171 803 811 O
, 171 172 811 812 O
prior 173 178 813 818 O
or 179 181 819 821 O
current 182 189 822 829 O
glaucoma 190 198 830 838 B-chronic_disease
, 198 199 838 839 O
narrow 200 206 840 846 B-chronic_disease
- 206 207 846 847 I-chronic_disease
angle 207 212 847 852 I-chronic_disease
glaucoma 213 221 853 861 I-chronic_disease
, 221 222 861 862 O
ongoing 223 230 863 870 O
eye 231 234 871 874 B-chronic_disease
infection 235 244 875 884 I-chronic_disease
, 244 245 884 885 O
uncontrolled 246 258 886 898 B-chronic_disease
hypertension 259 271 899 911 I-chronic_disease
, 271 272 911 912 O
known 273 278 913 918 O
/ 278 279 918 919 O
suspected 279 288 919 928 O
allergy 289 296 929 936 O
to 297 299 937 939 O
constituents 300 312 940 952 O
of 313 315 953 955 O
the 316 319 956 959 O
preparation 320 331 960 971 O
( 332 333 972 973 O
such 333 337 973 977 O
as 338 340 978 980 O
sodium 341 347 981 987 B-allergy_name
bisulfite 348 357 988 997 I-allergy_name
) 357 358 997 998 O

Eastern 0 7 999 1006 B-clinical_variable
Cooperative 8 19 1007 1018 I-clinical_variable
Oncology 20 28 1019 1027 I-clinical_variable
Group 29 34 1028 1033 I-clinical_variable
( 35 36 1034 1035 I-clinical_variable
ECOG 36 40 1035 1039 I-clinical_variable
) 40 41 1039 1040 I-clinical_variable
performance 42 53 1041 1052 I-clinical_variable
status 54 60 1053 1059 I-clinical_variable
more 61 65 1060 1064 O
than 66 70 1065 1069 O
1 71 72 1070 1071 B-lower_bound

Female 0 6 1072 1078 B-gender
or 7 9 1079 1081 I-gender
male 10 14 1082 1086 I-gender
patients 15 23 1087 1095 I-gender
with 24 28 1096 1100 O
reproductive 29 41 1101 1113 O
potential 42 51 1114 1123 O
who 52 55 1124 1127 O
do 56 58 1128 1130 B-contraception_consent
not 59 62 1131 1134 I-contraception_consent
agree 63 68 1135 1140 I-contraception_consent
to 69 71 1141 1143 I-contraception_consent
use 72 75 1144 1147 I-contraception_consent
an 76 78 1148 1150 I-contraception_consent
accepted 79 87 1151 1159 I-contraception_consent
effective 88 97 1160 1169 I-contraception_consent
method 98 104 1170 1176 I-contraception_consent
of 105 107 1177 1179 I-contraception_consent
contraception 108 121 1180 1193 I-contraception_consent
during 122 128 1194 1200 O
the 129 132 1201 1204 O
study 133 138 1205 1210 B-treatment
treatment 139 148 1211 1220 I-treatment
period 149 155 1221 1227 O
and 156 159 1228 1231 O
for 160 163 1232 1235 O
at 164 166 1236 1238 O
least 167 172 1239 1244 O
3 173 174 1245 1246 B-lower_bound
months 175 181 1247 1253 I-lower_bound
following 182 191 1254 1263 O
completion 192 202 1264 1274 O
of 203 205 1275 1277 O
study 206 211 1278 1283 O
treatment 212 221 1284 1293 O

Known 0 5 1294 1299 O
intolerance 6 17 1300 1311 O
to 18 20 1312 1314 O
infused 21 28 1315 1322 B-allergy_name
protein 29 36 1323 1330 I-allergy_name
products 37 45 1331 1339 I-allergy_name

Locally 0 7 1340 1347 O
advanced 8 16 1348 1356 O
or 17 19 1357 1359 O
metastatic 20 30 1360 1370 O
solid 31 36 1371 1376 O
malignant 37 46 1377 1386 B-cancer
tumor 47 52 1387 1392 I-cancer
disease 53 60 1393 1400 I-cancer
for 61 64 1401 1404 O
which 65 70 1405 1410 O
no 71 73 1411 1413 O
standard 74 82 1414 1422 O
alternative 83 94 1423 1434 B-treatment
therapy 95 102 1435 1442 I-treatment
is 103 105 1443 1445 O
available 106 115 1446 1455 O

Medical 0 7 1456 1463 B-chronic_disease
conditions 8 18 1464 1474 I-chronic_disease
requiring 19 28 1475 1484 O
concomitant 29 40 1485 1496 O
administration 41 55 1497 1511 O
of 56 58 1512 1514 O
medications 59 70 1515 1526 B-treatment
with 71 75 1527 1531 O
narrow 76 82 1532 1538 B-treatment
therapeutic 83 94 1539 1550 I-treatment
window 95 101 1551 1557 I-treatment
, 101 102 1557 1558 O
metabolized 103 114 1559 1570 O
by 115 117 1571 1573 O
cytochrome 118 128 1574 1584 B-clinical_variable
P450 129 133 1585 1589 I-clinical_variable
( 134 135 1590 1591 I-clinical_variable
CYPs 135 139 1591 1595 I-clinical_variable
) 139 140 1595 1596 I-clinical_variable
enzymes 141 148 1597 1604 I-clinical_variable
and 149 152 1605 1608 O
for 153 156 1609 1612 O
which 157 162 1613 1618 O
a 163 164 1619 1620 O
dose 165 169 1621 1625 O
reduction 170 179 1626 1635 O
can 180 183 1636 1639 O
not 183 186 1639 1642 O
be 187 189 1643 1645 O
considered 190 200 1646 1656 O

Medical 0 7 1657 1664 O
conditions 8 18 1665 1675 O
requiring 19 28 1676 1685 O
concomitant 29 40 1686 1697 O
administration 41 55 1698 1712 O
of 56 58 1713 1715 O
strong 59 65 1716 1722 B-treatment
CYP3A 66 71 1723 1728 I-treatment
inhibitor 72 81 1729 1738 I-treatment
, 81 82 1738 1739 O
unless 83 89 1740 1746 O
it 90 92 1747 1749 O
can 93 96 1750 1753 O
be 97 99 1754 1756 O
discontinued 100 112 1757 1769 O
at 113 115 1770 1772 O
least 116 121 1773 1778 O
2 122 123 1779 1780 B-lower_bound
weeks 124 129 1781 1786 I-lower_bound
before 130 136 1787 1793 O
1st 137 140 1794 1797 O
administration 141 155 1798 1812 O
of 156 158 1813 1815 O
SAR408701 159 168 1816 1825 B-treatment

Participation 0 13 1826 1839 O
to 14 16 1840 1842 O
any 17 20 1843 1846 O
clinical 21 29 1847 1855 O
research 30 38 1856 1864 O
study 39 44 1865 1870 O
evaluating 45 55 1871 1881 O
another 56 63 1882 1889 O
investigational 64 79 1890 1905 B-treatment
drug 80 84 1906 1910 I-treatment
or 85 87 1911 1913 O
therapy 88 95 1914 1921 B-treatment
within 96 102 1922 1928 O
3 103 104 1929 1930 B-upper_bound
weeks 105 110 1931 1936 I-upper_bound
of 111 113 1937 1939 O
initiation 114 124 1940 1950 O
of 125 127 1951 1953 O
study 128 133 1954 1959 O
regimen 134 141 1960 1967 O

Patients 0 8 1968 1976 O
with 9 13 1977 1981 O
malabsorption 14 27 1982 1995 B-chronic_disease
syndrome 28 36 1996 2004 I-chronic_disease

Poor 0 4 2005 2009 O
bone 5 9 2010 2014 O
marrow 10 16 2015 2021 O
reserve 17 24 2022 2029 O
resulting 25 34 2030 2039 O
in 35 37 2040 2042 O
low 38 41 2043 2046 O
blood 42 47 2047 2052 B-clinical_variable
cell 48 52 2053 2057 I-clinical_variable
counts 53 59 2058 2064 I-clinical_variable

Poor 0 4 2065 2069 B-chronic_disease
kidney 5 11 2070 2076 I-chronic_disease
and 12 15 2077 2080 I-chronic_disease
liver 16 21 2081 2086 I-chronic_disease
functions 22 31 2087 2096 I-chronic_disease

Pregnancy 0 9 2097 2106 B-pregnancy

Previous 0 8 2107 2115 O
history 9 16 2116 2123 O
and 17 20 2124 2127 O
or 21 23 2128 2130 O
unresolved 24 34 2131 2141 O
corneal 35 42 2142 2149 B-chronic_disease
disorders 43 52 2150 2159 I-chronic_disease

Prior 0 5 2160 2165 B-treatment
maytansinoid 6 18 2166 2178 I-treatment
treatments 19 29 2179 2189 I-treatment
( 30 31 2190 2191 O
DM1 31 34 2191 2194 B-treatment
or 35 37 2195 2197 O
DM4 38 41 2198 2201 B-treatment
antibody 42 50 2202 2210 I-treatment
drug 51 55 2211 2215 I-treatment
conjugates 56 66 2216 2226 I-treatment
) 66 67 2226 2227 O

Prior 0 5 2228 2233 B-treatment
therapy 6 13 2234 2241 I-treatment
targeting 14 23 2242 2251 I-treatment
CEACAM5 24 31 2252 2259 I-treatment

Unresolved 0 10 2260 2270 O
signs 11 16 2271 2276 O
and 17 20 2277 2280 O
symptoms 21 29 2281 2289 O
of 30 32 2290 2292 O
neuropathy 33 43 2293 2303 B-chronic_disease

any 0 3 2304 2307 O
other 4 9 2308 2313 O
clinically 10 20 2314 2324 O
significant 21 32 2325 2336 O
arrhythmias 33 44 2337 2348 B-chronic_disease

carcinoembryonic 0 16 2349 2365 B-clinical_variable
antigen 17 24 2366 2373 I-clinical_variable
( 25 26 2374 2375 I-clinical_variable
CEA 26 29 2375 2378 I-clinical_variable
) 29 30 2378 2379 I-clinical_variable
plasma 31 37 2380 2386 I-clinical_variable
levels 38 44 2387 2393 I-clinical_variable
> 45 46 2394 2395 O
5 46 47 2395 2396 B-lower_bound
ng 48 50 2397 2399 I-lower_bound
/ 50 51 2399 2400 I-lower_bound
mL 51 53 2400 2402 I-lower_bound

inadequate 0 10 2403 2413 O
wash 11 15 2414 2418 O
- 15 16 2418 2419 O
out 16 19 2419 2422 O
period 20 26 2423 2429 O
for 27 30 2430 2433 O
prior 31 36 2434 2439 B-treatment
anticancer 37 47 2440 2450 I-treatment
therapies 48 57 2451 2460 I-treatment
before 58 64 2461 2467 O
first 65 70 2468 2473 O
administration 71 85 2474 2488 O
of 86 88 2489 2491 O
SAR408701 89 98 2492 2501 B-treatment

non 0 3 2502 2505 O
- 3 4 2505 2506 O
resolution 4 14 2506 2516 O
of 15 17 2517 2519 O
toxicities 18 28 2520 2530 O
induced 29 36 2531 2538 O
by 37 39 2539 2541 O
these 40 45 2542 2547 O
anticancer 46 56 2548 2558 B-treatment
therapies 57 66 2559 2568 I-treatment

patients 0 8 2569 2577 O
with 9 13 2578 2582 O
CRC 14 17 2583 2586 B-cancer
or 18 20 2587 2589 O
with 21 25 2590 2594 O
CEACAM5 26 33 2595 2602 O
positive 34 42 2603 2611 O
non 43 46 2612 2615 O
- 46 47 2615 2616 O
squamous 47 55 2616 2624 O
NSCLC 56 61 2625 2630 B-cancer
, 61 62 2630 2631 O
small 63 68 2632 2637 B-cancer
cell 69 73 2638 2642 I-cancer
lung 74 78 2643 2647 I-cancer
cancer 79 85 2648 2654 I-cancer
( 86 87 2655 2656 I-cancer
SCLC 87 91 2656 2660 I-cancer
) 91 92 2660 2661 I-cancer
or 93 95 2662 2664 O
gastric 96 103 2665 2672 B-cancer
carcinoma 104 113 2673 2682 I-cancer
( 114 115 2683 2684 O
including 115 124 2684 2693 O
esophago 125 133 2694 2702 B-cancer
- 133 134 2702 2703 I-cancer
gastric 134 141 2703 2710 I-cancer
junction 142 150 2711 2719 I-cancer
adenocarcinoma 151 165 2720 2734 I-cancer
of 166 168 2735 2737 O
the 169 172 2738 2741 O
Siewert 173 180 2742 2749 B-clinical_variable
types 181 186 2750 2755 B-lower_bound
II 187 189 2756 2758 I-lower_bound
and 190 193 2759 2762 O
III 194 197 2763 2766 B-upper_bound
) 197 198 2766 2767 O

patients 0 8 2768 2776 O
with 9 13 2777 2781 O
tumors 14 20 2782 2788 B-cancer
expressing 21 31 2789 2799 O
or 32 34 2800 2802 O
likely 35 41 2803 2809 O
to 42 44 2810 2812 O
be 45 47 2813 2815 O
expressing 48 58 2816 2826 O
CEACAM5 59 66 2827 2834 O
which 67 72 2835 2840 O
includes 73 81 2841 2849 O
colorectal 82 92 2850 2860 B-cancer
cancer 93 99 2861 2867 I-cancer
( 100 101 2868 2869 I-cancer
CRC 101 104 2869 2872 I-cancer
) 104 105 2872 2873 I-cancer
, 105 106 2873 2874 O
non 107 110 2875 2878 B-cancer
- 110 111 2878 2879 I-cancer
squamous 111 119 2879 2887 I-cancer
non 120 123 2888 2891 I-cancer
- 123 124 2891 2892 I-cancer
small 124 129 2892 2897 I-cancer
cell 130 134 2898 2902 I-cancer
lung 135 139 2903 2907 I-cancer
cancer 140 146 2908 2914 I-cancer
( 147 148 2915 2916 I-cancer
NSCLC 148 153 2916 2921 I-cancer
) 153 154 2921 2922 I-cancer
, 154 155 2922 2923 O
gastric 156 163 2924 2931 B-cancer
adenocarcinoma 164 178 2932 2946 I-cancer
, 178 179 2946 2947 O
squamous 180 188 2948 2956 B-cancer
cell 189 193 2957 2961 I-cancer
carcinoma 194 203 2962 2971 I-cancer
of 204 206 2972 2974 I-cancer
the 207 210 2975 2978 I-cancer
cervix 211 217 2979 2985 I-cancer
, 217 218 2985 2986 O
pancreas 219 227 2987 2995 B-cancer
adenocarcinoma 228 242 2996 3010 I-cancer
, 242 243 3010 3011 O
bladder 244 251 3012 3019 O
transitional 252 264 3020 3032 B-cancer
cell 265 269 3033 3037 I-cancer
carcinoma 270 279 3038 3047 I-cancer
, 279 280 3047 3048 O
cholangiocarcinoma 281 299 3049 3067 B-cancer
, 299 300 3067 3068 O
epithelial 301 311 3069 3079 B-cancer
ovarian 312 319 3080 3087 I-cancer
cancer 320 326 3088 3094 I-cancer
and 327 330 3095 3098 O
endometrial 331 342 3099 3110 B-cancer
adenocarcinoma 343 357 3111 3125 I-cancer

